Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy

Justin Cidado, Ben Ho Park

Research output: Contribution to journalArticlepeer-review

53 Scopus citations


Recent advances in genetics and genomics have revealed new pathways that are aberrantly activated in many breast cancers. Chief among these genetic changes are somatic mutations and/or gains and losses of key genes within the phosphoinositide 3-kinase (PI3K) pathway. Since breast cancer cell growth and progression is often dependent upon activation of the PI3K pathway, there has been intense research interest in finding therapeutic agents that can selectively inhibit one or more constituents of this signaling cascade. Here we review key molecules involved with aberrant PI3K pathway activation in breast cancers and current efforts to target these components for therapeutic gain.

Original languageEnglish (US)
Pages (from-to)205-216
Number of pages12
JournalJournal of Mammary Gland Biology and Neoplasia
Issue number3-4
StatePublished - Dec 2012


  • Breast cancer
  • PI3 Kinase
  • PIK3CA
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy'. Together they form a unique fingerprint.

Cite this